For most of the past decade, healthcare supply chain leaders have been asked to do two things that pull in opposite directions: take cost out, and guarantee that the right product is at the bedside every time. In 2026 that tension has sharpened. The American Hospital Association reports that total hospital expenses grew 7.5% in 2025, more than twice the growth rate of hospital prices, with supply expenses up 9.9% and drug expenses up 13.6% (American Hospital Association [AHA], 2026). Meanwhile, active U.S. drug shortages rose for a third consecutive quarter, reaching 227 at the end of June 2026 (Fox & Ganio, 2026). With median hospital operating margins below 1% for much of the first half of the year (Southwick, 2026), there is little financial room to absorb either problem.
The argument of this article is that the next era of supply chain performance will be defined less by any single technology than by three disciplines working together: structural risk management, data integrity, and carefully governed automation, including the emerging class of agentic AI.
Resilience Is Structural, Not Episodic
The pandemic taught health systems to respond to disruption with war rooms and emergency sourcing. Current data suggest the vulnerabilities are not episodic but built into the market. Just under half (48%) of new drug shortages in 2026 involve sole-source products, meaning a single manufacturer’s disruption can remove an entire domestic supply with no immediate alternative (AJMC Staff, 2026). Sterile injectables account for 58% of new shortages (American Medical Association [AMA], 2026), and roughly 77% of active shortages began in 2022 or later (Becker’s Hospital Review, 2026b). Trade policy adds a further layer: in survey data summarized in the AHA’s 2026 Environmental Scan, 82% of respondents expected tariffs to raise hospital supply costs by at least 15%, and 90% of supply chain professionals anticipated procurement disruptions (Becker’s Hospital Review, 2026a).
The practical implication is that resilience should be managed as a standing portfolio discipline rather than a crisis response. Three moves stand out:
• Segment by risk, not just spend. Classify items by clinical criticality and supply concentration (sole-source, single geography, single plant). A low-cost item with no substitute can matter more than a high-spend commodity.
• Pre-approve alternatives. Work with pharmacy, nursing, and value analysis committees to define clinically acceptable substitutes before a shortage, not during one.
• Apply “just-in-case” selectively. Blanket stockpiling ties up cash that thin-margin organizations do not have. Strategic buffers belong on concentrated, critical items; lean replenishment still suits commodities with deep supplier bases.
Procurement: From Unit Price to Total Value
Price-focused contracting has delivered real savings, but it can also reward the market dynamics that leave generic and commodity products fragile. A more durable procurement strategy evaluates suppliers on reliability, manufacturing redundancy, and transparency into upstream (tier-two and tier-three) sources alongside price. Contract terms can reflect this through supply-assurance commitments, multi-award structures for critical categories, and data-sharing provisions on manufacturing sites and allocation practices.
The way the field recognizes excellence has shifted in the same direction. Gartner’s Healthcare Supply Chain Top 25, now in its 18th year, combines peer and analyst opinion with measures such as quality of patient care, financial strength, ESG performance, and risk management (Gartner, 2026; SupplyChain247, 2024). In other words, the benchmark for a strong supply chain is no longer what it saves, but how well it protects care while managing cost.
The Unglamorous Foundation: Data Integrity
Every advanced capability, whether predictive forecasting, automated substitution, or AI-driven sourcing, depends on knowing exactly what is being bought, where it is, and what it can be replaced with. That knowledge lives in the item master, which Berkeley Research Group describes as a critical source of truth for hospital operations; organizations that have clearly flagged preferred and non-preferred products in that file can pivot to alternatives quickly when disruption hits (Berkeley Research Group [BRG], 2026).
Yet supply chain data remains notoriously inconsistent. Industry observers note that the field still lacks a common language, which makes normalization and comparison across systems difficult (MedCity News, 2026). Adopting GS1 identifiers such as the Global Trade Item Number (GTIN) and Global Location Number (GLN), and capturing Unique Device Identifiers (UDI) at the point of use, gives organizations a shared vocabulary with suppliers and regulators (Association for Health Care Resource & Materials Management [AHRMM], n.d.). This work is rarely celebrated, but it is the precondition for everything that follows.
Agentic AI: Promise With Guardrails
Agentic AI refers to systems that pursue goals across multiple steps, monitoring signals, weighing options, and taking actions in enterprise systems within defined permissions, rather than simply answering questions or producing forecasts. Industry leaders anticipate that such agents will increasingly orchestrate replenishment, contracting, and supplier diversification ahead of disruptions (Managed Healthcare Executive [MHE] Staff, 2026). Plausible near-term uses include shortage early-warning (matching regulatory and supplier notices to the item master and current utilization), drafting substitution options for clinical review, resolving purchase-order and invoice exceptions, and classifying spend data that teams currently categorize by hand (MedCity News, 2026).
Enthusiasm should be tempered by evidence. In a Q1 2026 survey of 100 European pharmaceutical supply chain leaders, respondents viewed agentic AI as promising but not yet proven for disruption prediction and mitigation (WBR Insights, 2026). Health systems can capture value while managing risk by adopting a few governance principles:
• Tier the autonomy. Let agents act on low-risk, reversible transactions (routine reorders, exception routing); require human approval for anything touching clinical substitution, allocation, or contract terms.
• Make every action auditable. Agents should log the data, rules, and reasoning behind each action so supply chain, pharmacy, and compliance teams can review it.
• Measure outcomes, not activity. Judge deployments by stockouts avoided, fill rates, expedited-freight spend, and staff hours returned, not by the number of tasks automated.
Conclusion: Supply Chain as a Clinical Function
The most important shift in healthcare supply chain management is conceptual. When shortages are chronic and margins are thin, supply chain is not a back-office cost center; it is part of how care is delivered safely. Leaders can test their readiness with three questions. Do we know which items, if unavailable tomorrow, would most disrupt patient care? Is our product data trustworthy enough that an algorithm could safely act on it? And which decisions are we prepared to delegate to automated agents, and how will we know when one is wrong? Organizations that can answer these clearly will be best positioned to turn new technology into genuine resilience.
References
AJMC Staff. (2026, July 20). Active US drug shortages rise for third straight quarter. The American Journal of Managed Care. https://www.ajmc.com/view/active-us-drug-shortages-rise-for-third-straight-quarter
American Hospital Association. (2026, March 11). New AHA report: Hospitals face increased challenges and financial pressures as they care for patients [Press release].
American Medical Association. (2026). Drug shortages: Causes, consequences and mitigation efforts.
Association for Health Care Resource & Materials Management. (n.d.). GS1 standards at a hospital: A roadmap for implementation. https://www.ahrmm.org/resource-repository-ahrmm/gs1-standards-at-a-hospital-roadmap-for-implementation-on-demand-113017-1
Becker’s Hospital Review. (2026a). Hospitals faced tariff risk, rising supply costs in 2025.
Becker’s Hospital Review. (2026b). US drug shortages trending upward in 2026.
https://www.beckershospitalreview.com/pharmacy/us-drug-shortages-trending-upward-in-2026/
Berkeley Research Group. (2026, Summer). Healthcare supply chain resilience starts with reliable data. ThinkSet Magazine. https://thinkbrg.com/thinkset/healthcare-supply-chain-resilience-starts-with-reliable-data/
Fox, E. R., & Ganio, M. (2026). National drug shortages: January 2001–June 2026. American Society of Health-System Pharmacists and University of Utah Drug Information Service. https://www.ashp.org/-/media/assets/drug-shortages/docs/Drug-Shortages-Report.pdf
Gartner. (2026). Gartner Healthcare Supply Chain Top 25. https://www.gartner.com/en/supply-chain/research/gartner-healthcare-supply-chain-top-25
Managed Healthcare Executive Staff. (2026, January 7). Predictions about AI in 2026. Managed Healthcare Executive. https://managedhealthcareexecutive.com/view/predictions-about-ai-in-2026-from-chris-louma-courtney-bragg-mba-katerina-guerraz-m-p-h-and-others
MedCity News. (2026, April). Clinical supply chain hits its AI turning point. https://medcitynews.com/2026/04/clinical-supply-chain-hits-its-ai-turning-point/
Southwick, R. (2026, October 12). Hospitals are seeing slim margins in 2026. Chief Healthcare Executive. https://www.chiefhealthcareexecutive.com/view/hospitals-are-seeing-slim-margins-in-2026
SupplyChain247. (2024). Gartner unveils Healthcare Supply Chain Top 25, AdventHealth tops list. https://www.supplychain247.com/article/healthcare-supply-chain-top-25-rankings-gartner/Interlake_Mecalux
WBR Insights. (2026). LogiPharma: The 2026 playbook—Supply chain & logistics insights.